Search This Blog

Thursday, October 22, 2015

Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations (NYSE:LLY)

INDIANAPOLIS, Oct. 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.



Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations (NYSE:LLY)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)